Evidence map›Paper›PMID 42557955›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Predicting continuous amyloid PET levels with CSF and plasma brain-derived p-tau217.

Lydia Trudel, Joseph Therriault, Arthur C Macedo, Etienne Aumont, Seyyed Ali Hosseini, Andrea L Benedet, Lili-Naz Hazrati, Serge Gauthier, Henrik Zetterberg, Paolo Vitali and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lydia TrudelTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Montreal Neurological Institute, Montreal, Quebec, Canada.ORCID https://orcid.org/0009-0002-5593-7717
Joseph TherriaultTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Montreal Neurological Institute, Montreal, Quebec, Canada.
Arthur C MacedoTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Montreal Neurological Institute, Montreal, Quebec, Canada.
Etienne AumontTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Montreal Neurological Institute, Montreal, Quebec, Canada.
Seyyed Ali HosseiniTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Montreal Neurological Institute, Montreal, Quebec, Canada.
Andrea L BenedetDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Möldnal, Sweden.
Lili-Naz HazratiDepartment of Neuropathology, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Serge GauthierTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Montreal Neurological Institute, Montreal, Quebec, Canada.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Möldnal, Sweden.
Paolo VitaliTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Montreal Neurological Institute, Montreal, Quebec, Canada.
Nicholas J AshtonDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Möldnal, Sweden.
Pedro Rosa-NetoTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Montreal Neurological Institute, Montreal, Quebec, Canada.
Alzheimer's Disease Neuroimaging Initiative

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Alzheimer's AssociationAlzheimer's Disease Neuroimaging Initiative (ADNI); National Institutes of Health U01 AG024904Canadian Consortium of Neurodegeneration and Aging (CCNA) MOP-11-51-31 -team 1Canadian Institutes of Health Research (CIHR) MOP-11-51-31Canadian Institutes of Health Research (CIHR) RFN 152985 159815 162303Consortium canadien en neurodégénérescence associée au vieillissementEuropean Union's Horizon Europe research and innovation programme 101053962Fondation Brain CanadaNIA NIH HHS U01 AG024904Swedish State Support for Clinical Research #ALFGBG-71320the Alzheimer's Association 33397the Alzheimer's Association 34874the Alzheimer's Association NIRG-12-92090 NIRP-12-259245the Fonds de Recherche du Québec - Santéthe Fonds de Recherche du Québec - Santé (FRQS); Chercheur Boursier 2020-VICO-279314the Fonds de Recherche du Québec - Santé (FRQS); Chercheur Boursier 2024-VICO-356138the Swedish Research CouncilWeston Brain Institute
6 · The paper itself

Abstract

backgroundStaging amyloid beta (Aβ) burden along a continuous spectrum provides clinically relevant information. Conventional phosphorylated tau (p-tau)217 reliably identifies amyloid positron emission tomography (PET) positivity, but its ability to capture the full Aβ continuum is limited. Recently developed brain-derived (BD) p-tau217 assays enrich for central nervous system tau species and may improve specificity.

methodsWe tested how closely BD p-tau217 reflected continuous Aβ and how accurately it could classify participants as Aβ positive or negative across different Centiloid (CL) thresholds in 924 participants from the Alzheimer's Disease Neuroimaging Initiative. Conventional and BD cerebrospinal fluid (CSF) and plasma p-tau217 biomarkers were quantified using the Alamar NULISAseq panel.

resultsAcross the full cohort, plasma BD p-tau217 demonstrated the strongest continuous association with PET CL (R

conclusionsPlasma BD p-tau217 best captured the amyloid PET continuum, with BD processing improving discrimination in plasma but not CSF.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBrainPositron-Emission Tomographytau ProteinsAgedBiomarkersFemaleHumansMalePhosphorylationAmyloid beta-PeptidesBiomarkerstau ProteinsAlzheimer's diseasebrain‐derived phosphorylated tau217cerebrospinal fluid biomarkersplasma biomarkers

Identifiers

PMID42557955
PMCPMC13444719

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.